Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH)
Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH) is a PHASE2 clinical asset sponsored by Central Hospital, Nancy, France in Non-alcoholic Steatohepatitis. SEO and diligence focus: PET scan of 68Ga-FAPI, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Non-alcoholic Steatohepatitis
Modality: small molecule
Target: PET scan of 68Ga-FAPI
Sponsor: Central Hospital, Nancy, France
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: PET scan of 68Ga-FAPI
View original source fields
Condition raw: Non-alcoholic Steatohepatitis
Condition normalized: Non-alcoholic Steatohepatitis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: PET scan of 68Ga-FAPI
Target normalized: PET scan of 68Ga-FAPI